<p>Allspring Global Investments Holdings LLC 在最近向证券交易委员会（SEC）提交的 13F 文件中表示，在第三季度将其在 Enovis Corporation（纽约证券交易所代码：ENOV - 免费报告）的持股减少了 16.2%。该机构投资者在季度内出售了 131,595 股后，持有该公司 679,176 股股票。截至其最近向证券交易委员会（SEC）提交的文件，Allspring Global Investments Holdings LLC 持有约 1.19% 的 Enovis，价值 20,688,000 美元。</p>
<p>其他几家大型投资者最近也买卖了该公司的股票。Farther Finance Advisors LLC 在第三季度将其在 Enovis 的持股增加了 42.8%。Farther Finance Advisors LLC 现在持有 1,224 股该公司的股票，价值 37,000 美元，此前在该期间内又购买了 367 股。EverSource Wealth Advisors LLC 在第二季度将其在 Enovis 的持股增加了 125.4%。EverSource Wealth Advisors LLC 现在持有 1,271 股该公司的股票，价值 40,000 美元，此前在上个季度又购买了 707 股。Elevation Point Wealth Partners LLC 在第二季度购买了 Enovis 的新头寸，价值约 46,000 美元。CWM LLC 在第二季度将其在 Enovis 的持股增加了 564.9%。CWM LLC 现在持有 3,790 股该公司的股票，价值 119,000 美元，此前在上个季度又收购了 3,220 股。最后，Tower Research Capital LLC TRC 在第二季度将其在 Enovis 的持股增加了 578.2%。Tower Research Capital LLC TRC 现在持有 4,347 股该公司的股票，价值 136,000 美元，此前在上个季度又收购了 3,706 股。98.45% 的股票由机构投资者持有。</p>
<h2>Enovis 的内部活动</h2>
<p>在 Enovis 的其他新闻中，执行副总裁 Daniel A. Pryor 于 12 月 9 日星期二出售了 999 股 Enovis 股票。该股票以平均价格 27.20 美元出售，总价值为 27,172.80 美元。此次出售在向 SEC 的法律文件中披露，相关信息可通过 SEC 网站访问。此外，内部人士 John Kleckner 于 11 月 25 日星期二收购了 2,468 股该股票。该股票以每股平均价格 30.32 美元购买，总价值为 74,829.76 美元。交易后，该内部人士直接持有 12,302 股该公司的股票，价值约 372,996.64 美元。此次交易使其持股增加了 25.10%。此次购买的披露信息可在 SEC 文件中找到。2.70% 的股票由公司内部人士持有。</p>
<h2>分析师的升级和降级</h2>
<p>ENOV 最近成为多份分析师报告的主题。Canaccord Genuity Group 将 Enovis 的目标价格从 58.00 美元下调至 50.00 美元，并在 12 月 17 日星期三的研究报告中对该股票给予 “买入” 评级。Wells Fargo &amp; Company 将 Enovis 的目标价格从 41.00 美元上调至 42.00 美元，并在 11 月 7 日星期五的报告中给予该股票 “增持” 评级。最后，Weiss Ratings 在 10 月 8 日星期三的报告中重申了对 Enovis 的 “卖出（d-）” 评级。六位研究分析师对该股票给予了买入评级，一位分析师给予了卖出评级。根据 MarketBeat 的数据，Enovis 目前的共识评级为 “适度买入”，平均目标价格为 49.83 美元。</p>
<p><strong>查看我们对 Enovis 的最新分析</strong></p>
<h2>Enovis 的价格表现</h2>
<p>纽约证券交易所代码：ENOV 的股票在周五开盘价为 26.44 美元。该公司的速动比率为 1.16，流动比率为 2.22，债务与股本比率为 0.66。该股票的市值为 15.1 亿美元，市盈率为 -1.12，贝塔系数为 1.52。该公司的 50 日移动平均线为 28.72 美元，200 日移动平均线为 29.98 美元。Enovis Corporation 的 52 周低点为 25.47 美元，52 周高点为 49.38 美元。</p>
<p>Enovis（纽约证券交易所代码：ENOV - 获取免费报告）最后一次公布季度财报是在 1 月 8 日星期一。该公司报告季度每股收益（EPS）为 0.59 美元。该公司季度收入为 3.8381 亿美元。Enovis 的股本回报率为 7.79%，净利润率为 -61.22%。研究分析师预计 Enovis Corporation 在本年度将发布 2.79 美元的每股收益。</p>
<h2>Enovis 公司简介</h2>
<p>（免费报告）</p>
<p>Enovis 是一家全球医疗技术公司，专注于推进肌肉骨骼健康领域。该公司于 2021 年通过将 MedTech 业务从 Colfax Corporation 分离而成立，Enovis 汇集了一系列专门的产品和服务，旨在解决影响脚踝、手腕、运动医学、关节修复、生物制剂和康复的疾病。</p>
<p>该公司的旗舰产品包括 Treace Medical Concepts 品牌的足踝手术微创植入物和仪器、通过 Arthrosurface 提供的局部关节表面重塑植入物，以及以 NovaBone 市场销售的合成骨移植替代品。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更喜欢的五只股票超过 Enovis</li>
<li>崩盘前一个月</li>
<li>埃隆将 SpaceX 公开上市！$100 的 IPO 前机会！</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地激活</li>
<li>最后的黄金牛市</li>
<li>家族信托如何帮助保护您的财富</li>
</ul>
<p><strong>想看看其他对 ENOV 持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取 Enovis Corporation（纽约证券交易所代码：ENOV - 免费报告）的最新 13F 文件和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVOT1Y?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVOT1Y"/></p>
<p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Enovis 吗？</h2>
<p>在考虑 Enovis 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Enovis 并不在名单上。</p>
<p>虽然 Enovis 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

ENOV

<p>Allspring Global Investments Holdings LLC 在第三季度减少了对 Enovis Corporation (NYSE:ENOV) 的持股比例，下降了 16.2%，目前持有 679,176 股，价值约为 2070 万美元。其他投资者，包括 Farther Finance Advisors 和 CWM LLC 也调整了他们的持仓。分析师对 Enovis 的评级各不相同，普遍评级为 “适度买入”，平均目标价为 49.83 美元。Enovis 的股票开盘价为 26.44 美元，市值为 15.1 亿美元，市盈率为 -1.12。该公司报告了上个季度每股收益为 0.59 美元</p>

<p>Allspring Global Investments Holdings LLC cut its position in Enovis Corporation (NYSE:ENOV - Free Report) by 16.2% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 679,176 shares of the company's stock after selling 131,595 shares during the quarter. Allspring Global Investments Holdings LLC owned about 1.19% of Enovis worth $20,688,000 as of its most recent filing with the Securities and Exchange Commission (SEC).</p>
<div class="lb-trans"><p>Allspring Global Investments Holdings LLC 在最近向证券交易委员会（SEC）提交的 13F 文件中表示，在第三季度将其在 Enovis Corporation（纽约证券交易所代码：ENOV - 免费报告）的持股减少了 16.2%。该机构投资者在季度内出售了 131,595 股后，持有该公司 679,176 股股票。截至其最近向证券交易委员会（SEC）提交的文件，Allspring Global Investments Holdings LLC 持有约 1.19% 的 Enovis，价值 20,688,000 美元。</p>
</div><p>Several other large investors have also recently bought and sold shares of the company. Farther Finance Advisors LLC increased its holdings in shares of Enovis by 42.8% in the third quarter. Farther Finance Advisors LLC now owns 1,224 shares of the company's stock worth $37,000 after purchasing an additional 367 shares during the period. EverSource Wealth Advisors LLC grew its position in Enovis by 125.4% during the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company's stock worth $40,000 after buying an additional 707 shares in the last quarter. Elevation Point Wealth Partners LLC bought a new position in Enovis in the 2nd quarter worth about $46,000. CWM LLC raised its holdings in shares of Enovis by 564.9% in the 2nd quarter. CWM LLC now owns 3,790 shares of the company's stock valued at $119,000 after acquiring an additional 3,220 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its position in shares of Enovis by 578.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,347 shares of the company's stock valued at $136,000 after acquiring an additional 3,706 shares during the last quarter. 98.45% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>其他几家大型投资者最近也买卖了该公司的股票。Farther Finance Advisors LLC 在第三季度将其在 Enovis 的持股增加了 42.8%。Farther Finance Advisors LLC 现在持有 1,224 股该公司的股票，价值 37,000 美元，此前在该期间内又购买了 367 股。EverSource Wealth Advisors LLC 在第二季度将其在 Enovis 的持股增加了 125.4%。EverSource Wealth Advisors LLC 现在持有 1,271 股该公司的股票，价值 40,000 美元，此前在上个季度又购买了 707 股。Elevation Point Wealth Partners LLC 在第二季度购买了 Enovis 的新头寸，价值约 46,000 美元。CWM LLC 在第二季度将其在 Enovis 的持股增加了 564.9%。CWM LLC 现在持有 3,790 股该公司的股票，价值 119,000 美元，此前在上个季度又收购了 3,220 股。最后，Tower Research Capital LLC TRC 在第二季度将其在 Enovis 的持股增加了 578.2%。Tower Research Capital LLC TRC 现在持有 4,347 股该公司的股票，价值 136,000 美元，此前在上个季度又收购了 3,706 股。98.45% 的股票由机构投资者持有。</p>
</div><h2>Insider Activity at Enovis</h2>
<div class="lb-trans"><h2>Enovis 的内部活动</h2>
</div><p>In other Enovis news, EVP Daniel A. Pryor sold 999 shares of Enovis stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an average price of $27.20, for a total value of $27,172.80. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider John Kleckner acquired 2,468 shares of the stock in a transaction on Tuesday, November 25th. The stock was bought at an average price of $30.32 per share, with a total value of $74,829.76. Following the transaction, the insider directly owned 12,302 shares of the company's stock, valued at approximately $372,996.64. The trade was a 25.10% increase in their position. The disclosure for this purchase is available in the SEC filing. 2.70% of the stock is owned by company insiders.</p>
<div class="lb-trans"><p>在 Enovis 的其他新闻中，执行副总裁 Daniel A. Pryor 于 12 月 9 日星期二出售了 999 股 Enovis 股票。该股票以平均价格 27.20 美元出售，总价值为 27,172.80 美元。此次出售在向 SEC 的法律文件中披露，相关信息可通过 SEC 网站访问。此外，内部人士 John Kleckner 于 11 月 25 日星期二收购了 2,468 股该股票。该股票以每股平均价格 30.32 美元购买，总价值为 74,829.76 美元。交易后，该内部人士直接持有 12,302 股该公司的股票，价值约 372,996.64 美元。此次交易使其持股增加了 25.10%。此次购买的披露信息可在 SEC 文件中找到。2.70% 的股票由公司内部人士持有。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师的升级和降级</h2>
</div><p>ENOV has been the topic of a number of recent analyst reports. Canaccord Genuity Group lowered their target price on shares of Enovis from $58.00 to $50.00 and set a &#34;buy&#34; rating on the stock in a research note on Wednesday, December 17th. Wells Fargo &amp; Company increased their price target on shares of Enovis from $41.00 to $42.00 and gave the stock an &#34;overweight&#34; rating in a report on Friday, November 7th. Finally, Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Enovis in a report on Wednesday, October 8th. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Enovis presently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $49.83.</p>
<div class="lb-trans"><p>ENOV 最近成为多份分析师报告的主题。Canaccord Genuity Group 将 Enovis 的目标价格从 58.00 美元下调至 50.00 美元，并在 12 月 17 日星期三的研究报告中对该股票给予 “买入” 评级。Wells Fargo &amp; Company 将 Enovis 的目标价格从 41.00 美元上调至 42.00 美元，并在 11 月 7 日星期五的报告中给予该股票 “增持” 评级。最后，Weiss Ratings 在 10 月 8 日星期三的报告中重申了对 Enovis 的 “卖出（d-）” 评级。六位研究分析师对该股票给予了买入评级，一位分析师给予了卖出评级。根据 MarketBeat 的数据，Enovis 目前的共识评级为 “适度买入”，平均目标价格为 49.83 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on Enovis</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Enovis 的最新分析</strong></p>
</div><h2>Enovis Price Performance</h2>
<div class="lb-trans"><h2>Enovis 的价格表现</h2>
</div><p>Shares of NYSE:ENOV opened at $26.44 on Friday. The company has a quick ratio of 1.16, a current ratio of 2.22 and a debt-to-equity ratio of 0.66. The stock has a market cap of $1.51 billion, a PE ratio of -1.12 and a beta of 1.52. The company's fifty day moving average is $28.72 and its 200 day moving average is $29.98. Enovis Corporation has a 52 week low of $25.47 and a 52 week high of $49.38.</p>
<div class="lb-trans"><p>纽约证券交易所代码：ENOV 的股票在周五开盘价为 26.44 美元。该公司的速动比率为 1.16，流动比率为 2.22，债务与股本比率为 0.66。该股票的市值为 15.1 亿美元，市盈率为 -1.12，贝塔系数为 1.52。该公司的 50 日移动平均线为 28.72 美元，200 日移动平均线为 29.98 美元。Enovis Corporation 的 52 周低点为 25.47 美元，52 周高点为 49.38 美元。</p>
</div><p>Enovis (NYSE:ENOV - Get Free Report) last announced its quarterly earnings data on Monday, January 8th. The company reported $0.59 earnings per share (EPS) for the quarter. The firm had revenue of $383.81 million for the quarter. Enovis had a positive return on equity of 7.79% and a negative net margin of 61.22%. Research analysts anticipate that Enovis Corporation will post 2.79 earnings per share for the current year.</p>
<div class="lb-trans"><p>Enovis（纽约证券交易所代码：ENOV - 获取免费报告）最后一次公布季度财报是在 1 月 8 日星期一。该公司报告季度每股收益（EPS）为 0.59 美元。该公司季度收入为 3.8381 亿美元。Enovis 的股本回报率为 7.79%，净利润率为 -61.22%。研究分析师预计 Enovis Corporation 在本年度将发布 2.79 美元的每股收益。</p>
</div><h2>Enovis Company Profile</h2>
<div class="lb-trans"><h2>Enovis 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.</p>
<div class="lb-trans"><p>Enovis 是一家全球医疗技术公司，专注于推进肌肉骨骼健康领域。该公司于 2021 年通过将 MedTech 业务从 Colfax Corporation 分离而成立，Enovis 汇集了一系列专门的产品和服务，旨在解决影响脚踝、手腕、运动医学、关节修复、生物制剂和康复的疾病。</p>
</div><p>The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.</p>
<div class="lb-trans"><p>该公司的旗舰产品包括 Treace Medical Concepts 品牌的足踝手术微创植入物和仪器、通过 Arthrosurface 提供的局部关节表面重塑植入物，以及以 NovaBone 市场销售的合成骨移植替代品。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Enovis</li>
<li>A month before the crash</li>
<li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li>
<li>A U.S. “birthright” claim worth trillions - activated quietly</li>
<li>The Last Gold Bull Market</li>
<li>How a Family Trust May Be Able To Help Preserve Your Wealth</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更喜欢的五只股票超过 Enovis</li>
<li>崩盘前一个月</li>
<li>埃隆将 SpaceX 公开上市！$100 的 IPO 前机会！</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地激活</li>
<li>最后的黄金牛市</li>
<li>家族信托如何帮助保护您的财富</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding ENOV?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enovis Corporation (NYSE:ENOV - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 ENOV 持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取 Enovis Corporation（纽约证券交易所代码：ENOV - 免费报告）的最新 13F 文件和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVOT1Y" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=ENOV"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Enovis Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Enovis 吗？</h2>
</div><p>Before you consider Enovis, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Enovis 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enovis wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Enovis 并不在名单上。</p>
</div><p>While Enovis currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Enovis 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Allspring Global Investments Holdings LLC 削减了其在 Enovis 公司$ENOV 的股票持仓